Search

Displaying results 2371 - 2380 of 6196 in total
  1. Indication

    Cataract development

    go.drugbank.com/conditions/DBCOND0096028
    Drugs: Azapentacene · Bendazac · Pirenoxine
    Synonyms: Cat. - cataract
  2. Drug

    Uric acid

    go.drugbank.com/drugs/DB08844
    Investigational

    Normally a small amount of uric acid is present in the body, but when there is an excess amount in the blood, called hyperuricemia, this can lead to gout and formation of kidney stones. … In one country, Spain, uric acid is an investigational drug in a phase 3 trial studying its effects as an adjunct to alteplase in acute ischemic stroke.

  3. Drug

    Cilansetron

    go.drugbank.com/drugs/DB04885
    Experimental

    Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.

  4. Indication

    Lenticular opacities

    go.drugbank.com/conditions/DBCOND0010192
    Drugs: Bendazac
    Synonyms: Cat. - cataract
  5. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3). It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and ha...

  6. Drug

    Amsacrine

    go.drugbank.com/drugs/DB00276
    ApprovedInvestigationalWithdrawn

    It produces consistent but acceptable myelosuppression and cardiotoxic effects. … It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors.

  7. Drug

    Loracarbef

    go.drugbank.com/drugs/DB00447
    ApprovedWithdrawn

    Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.

  8. Drug

    Nivolumab

    go.drugbank.com/drugs/DB09035
    ApprovedInvestigational

    [A35203] It was developed by Bristol Myers Squibb.[L12129] Nivolumab was granted FDA approval on 22 December 2014.

  9. Drug

    Emicizumab

    go.drugbank.com/drugs/DB13923
    ApprovedInvestigational

    Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co. … The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents.

  10. Drug

    Fusarium oxysporum vasinfectum

    go.drugbank.com/drugs/DB10435
    Approved

    Fusarium oxysporum vasinfectum is a fungus which can provoke allergic reactions. Fusarium oxysporum vasinfectum extract is used in allergenic testing.